Lifeward Ltd. 8K

Lifeward Ltd. completed a cash-enhancing strategic Oratech/Oramed transaction and new technology acquisitions while reporting weaker Q1 2026 revenues, higher GAAP losses, and a delay in filing its Form 10-Q to finalize transaction accounting.

Lifeward Ltd. reported its unaudited first quarter 2026 results, highlighting completion of an equity-based strategic transaction with Oramed/Oratech that brought in $10 million of financing, $6.5 million of acquired cash, and a Protein Oral Delivery biomed platform with lead oral insulin asset ORMD-0801 moving toward a Phase 2 trial, alongside an agreement to acquire upper-body powered exoskeleton technology and improved cash utilization that reduced quarterly operating cash burn by 33% year-over-year; however, the company also disclosed a 22% revenue decline to $3.9 million, materially higher GAAP operating and net losses driven by a $4.9 million one-time in-process R&D charge from the Oratech transaction, and announced that it will delay filing its Form 10-Q for the quarter ended March 31, 2026 to complete accounting and financial reporting for the strategic transaction.

Filing Facts

CIK

1607962

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-002727

Alert Tier

7